Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,727.09
(
0.41%
)
US TECH 100
24,166.40
(
0.63%
)
Dow Jones
47,091.48
(
0.31%
)
Brent Oil
100.56
(
2.29%
)
Bitcoin
74,681.60
(
-0.22%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: A deleted message

Tuesday, 04/13/2010 12:33:57 PM

Tuesday, April 13, 2010 12:33:57 PM

Post# of 257251
New IDIX info that hasn’t been reported anywhere, to my knowledge: A few days ago, GSK (d/b/a ViiV Healthcare) started a drug-drug-interaction study of IDX899 and MRK’s Isentress (note that GSK2248761 is another name for IDX899):

http://clinicaltrials.gov/ct2/show/NCT01101893

This trial was entered into the clinicaltrials.gov database on 4/8/10.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now